275 related articles for article (PubMed ID: 23591842)
1. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
[TBL] [Abstract][Full Text] [Related]
2. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.
Marzinke MA; Choi CH; Chen L; Shih IeM; Chan DW; Zhang H
Mol Cell Proteomics; 2013 Feb; 12(2):356-68. PubMed ID: 23172893
[TBL] [Abstract][Full Text] [Related]
5. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
6. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
7. Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
Smith-Beckerman DM; Fung KW; Williams KE; Auersperg N; Godwin AK; Burlingame AL
Mol Cell Proteomics; 2005 Feb; 4(2):156-68. PubMed ID: 15591324
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
9. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
Morita A; Miyagi E; Yasumitsu H; Kawasaki H; Hirano H; Hirahara F
Proteomics; 2006 Nov; 6(21):5880-90. PubMed ID: 17022098
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.
Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX
J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
12. Proteomics for discovery of candidate colorectal cancer biomarkers.
Alvarez-Chaver P; Otero-Estévez O; Páez de la Cadena M; Rodríguez-Berrocal FJ; Martínez-Zorzano VS
World J Gastroenterol; 2014 Apr; 20(14):3804-24. PubMed ID: 24744574
[TBL] [Abstract][Full Text] [Related]
13. MASS SPECTROMETRY-BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS.
Li N; Zhan X
Mass Spectrom Rev; 2020 Sep; 39(5-6):471-498. PubMed ID: 32020673
[TBL] [Abstract][Full Text] [Related]
14. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
15. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis.
Guo X; Hao Y; Kamilijiang M; Hasimu A; Yuan J; Wu G; Reyimu H; Kadeer N; Abudula A
Tumour Biol; 2015 Mar; 36(3):1711-20. PubMed ID: 25427637
[TBL] [Abstract][Full Text] [Related]
16. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
Pitteri SJ; JeBailey L; Faça VM; Thorpe JD; Silva MA; Ireton RC; Horton MB; Wang H; Pruitt LC; Zhang Q; Cheng KH; Urban N; Hanash SM; Dinulescu DM
PLoS One; 2009 Nov; 4(11):e7916. PubMed ID: 19936259
[TBL] [Abstract][Full Text] [Related]
17. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
18. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Tchabo NE; Liel MS; Kohn EC
Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
20. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
Posadas EM; Davidson B; Kohn EC
Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
